US · VERU · BIOTECHNOLOGY
Veru Inc. (VERU) intrinsic value and stock valuation
$1.94as of 2026-11-21 · Mkt cap 37.4M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Veru Inc. DCF and intrinsic value
InvestorsCraft values VERU with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VERU’s statements →
Veru Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $16.9M | $16.3M | $39.4M | $61.3M |
| Operating income | -$-24.75M | -$-36.92M | -$-93.78M | -$-83.22M | $13M |
| Net income | -$-22.73M | -$-37.8M | -$-93.15M | -$-83.78M | $7.39M |
| EPSd | -$-1.55M | -$-2.8M | -$-10.96M | -$-10.46M | $881.9K |
| Operating cash flow | -$-30.04M | -$-21.68M | -$-88.01M | -$-47.51M | -$-15.57M |
| Capital expenditure | -$0.00 | -$-160K | -$-670K | -$-730K | -$-380K |
| Free cash flow | -$-30.04M | -$-21.84M | -$-88.68M | -$-48.24M | -$-15.95M |
| Total assets | $29.8M | $60.4M | $50M | $135.4M | $178.2M |
| Total debt | $3.12M | $13.9M | $14.4M | $15.9M | $13.7M |
| Net debt | -$-12.68M | -$-11.05M | $4.78M | -$-64.31M | -$-108.61M |
| Total equity | $18.3M | $32.3M | $19.7M | $82.8M | $152.3M |
| Cash and short-term investments | $18.3M | $24.9M | $9.63M | $80.2M | $122.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $16.9M | $16.3M | $39.4M | $61.3M |
| Cost of revenue | $150K | $11M | $8.73M | $8.76M | $13.3M |
| Gross profit | -$-150K | $5.85M | $7.57M | $30.6M | $47.9M |
| Research and development expenses | $15.6M | $12.8M | $51.2M | $70.7M | $32.7M |
| Selling, general and administrative expenses | $19.9M | $31.2M | $48.1M | $43.2M | $20.7M |
| Other expenses | -$-10.78M | -$-1.22M | $2.09M | $0.00 | $0.00 |
| Operating expenses | $24.8M | $42.8M | $101.4M | $113.8M | $53.4M |
| Cost and expenses | $24.8M | $53.8M | $110.1M | $122.6M | $48.3M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $610K | $2.43M | $4.37M | $4.89M |
| Depreciation and amortization | $150K | $270K | $270K | $210K | $590K |
| Ebitda | -$-35.38M | -$-36.2M | -$-89.98M | -$-79.23M | $9.75M |
| Operating income | -$-24.75M | -$-36.92M | -$-93.78M | -$-83.22M | $13M |
| Total other income/expenses, net | $9.07M | -$-160K | $1.11M | -$-580K | -$-8.71M |
| Income before tax | -$-15.68M | -$-37.08M | -$-92.67M | -$-83.8M | $4.27M |
| Income tax expense | $0.00 | $730K | $480K | $240K | -$-3.13M |
| Net income | -$-22.73M | -$-37.8M | -$-93.15M | -$-83.78M | $7.39M |
| Weighted average shares outstanding | $14.7M | $13.5M | $8.5M | $8.01M | $7.63M |
| Weighted average diluted shares outstanding | $14.7M | $13.5M | $8.5M | $8.01M | $8.38M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $18.3M | $24.9M | $9.63M | $80.2M | $122.4M |
| Net receivables | $0.00 | $3.96M | $4.51M | $3.55M | $13.8M |
| Inventory | $0.00 | $4.14M | $6.7M | $8.62M | $5.57M |
| Total current assets | $18.9M | $35.2M | $22.9M | $104M | $151.8M |
| Property, plant and equipment, net | $3.11M | $4.85M | $5.99M | $5.97M | $1.56M |
| Goodwill and intangible assets | $6.88M | $6.88M | $6.88M | $10.9M | $10.9M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | -$-1.56M |
| Total non-current assets | $10.9M | $25.2M | $27.1M | $31.4M | $26.4M |
| Total assets | $29.8M | $60.4M | $50M | $135.4M | $178.2M |
| Accounts payable | $3.12M | $3.04M | $12.9M | $22M | $3.41M |
| Short-term debt | $760K | $2.09M | $1.9M | $2.13M | $3.74M |
| Deferred revenue | $0.00 | $400K | $100K | $0.00 | $130K |
| Total current liabilities | $7.79M | $11.9M | $17.8M | $38.7M | $15.8M |
| Long-term debt | $2.36M | $11.8M | $12.5M | $13.8M | $10M |
| Deferred revenue, non-current | $0.00 | $0.00 | -$-450K | $0.00 | $0.00 |
| Total non-current liabilities | $3.72M | $16.2M | $12.5M | $13.9M | $10.1M |
| Capital lease obligations | $3.12M | $3.99M | $4.67M | $5.05M | $1.11M |
| Total liabilities | $11.5M | $28.1M | $30.3M | $52.6M | $25.9M |
| Common stock | $150K | $1.49M | $940K | $830K | $820K |
| Retained earnings | -$-317.3M | -$-294.57M | -$-256.77M | -$-163.62M | -$-81.8M |
| Accumulated other comprehensive income (loss) | $0.00 | -$-580K | -$-580K | -$-580K | -$-580K |
| Total equity | $18.3M | $32.3M | $19.7M | $82.8M | $152.3M |
| Total investments | $2.53M | $0.00 | $0.00 | $0.00 | -$-1.56M |
| Total debt | $3.12M | $13.9M | $14.4M | $15.9M | $13.7M |
| Net debt | -$-12.68M | -$-11.05M | $4.78M | -$-64.31M | -$-108.61M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-22.73M | -$-37.8M | -$-93.15M | -$-83.78M | $7.39M |
| Depreciation and amortization | $150K | $270K | $270K | $210K | $210K |
| Stock-based compensation | $8.1M | $13.6M | $17.9M | $11.2M | $5.05M |
| Change in working capital | -$-4.13M | $220K | -$-15.15M | $25.9M | -$-7.28M |
| Accounts receivable | -$-660K | $550K | -$-4.15M | $4.54M | -$-3.56M |
| Inventory | $860K | $990K | $650K | -$-3.13M | $550K |
| Accounts payable | -$-2.76M | -$-5.43M | -$-7.43M | $18.6M | $600K |
| Net cash provided by operating activities | -$-30.04M | -$-21.68M | -$-88.01M | -$-47.51M | -$-15.57M |
| Investments in property, plant and equipment | -$0.00 | -$-160K | -$-670K | -$-730K | -$-380K |
| Acquisitions, net | $24.8M | $0.00 | $0.00 | $5M | $15M |
| Net cash used for investing activities | $25.1M | $150K | $6.33M | $4.27M | $14.6M |
| Common stock issued | $0.00 | $35.3M | $6.01M | $1.08M | $108.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-4.22M | $36.8M | $11.1M | $1.07M | $109.7M |
| Net change in cash | -$-9.12M | $15.3M | -$-70.57M | -$-42.17M | $108.8M |
| Cash at end of period | $15.8M | $24.9M | $9.63M | $80.2M | $122.4M |
| Operating cash flow | -$-30.04M | -$-21.68M | -$-88.01M | -$-47.51M | -$-15.57M |
| Capital expenditure | -$0.00 | -$-160K | -$-670K | -$-730K | -$-380K |
| Free cash flow | -$-30.04M | -$-21.84M | -$-88.68M | -$-48.24M | -$-15.95M |
Line items
Line items
Line items
About Veru Inc.
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
- CEO
- Mitchell S. Steiner
- Employees
- 20
- Beta
- -1.18
Explore
Frequently asked questions
What is the intrinsic value of Veru Inc. (VERU)?
InvestorsCraft does not currently publish an intrinsic value for VERU. How the IC value is calculated.
Is VERU undervalued?
InvestorsCraft does not publish an undervaluation signal for VERU at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.